(RTTNews) - ADC Therapeutics SA (ADCT) reported a net loss for the quarter ended December 31, 2025, of $6.4 million, or a net loss of $0.04 per share, as compared to net loss of $30.7 million, or a net loss of $0.29 per share, prior year. Adjusted net loss was $13.5 million, or an adjusted net loss of $0.09 per share as compared to an adjusted net loss of $26.5 million, or $0.25 share, a year ago.
Net product revenues were $22.3 million for the fourth quarter as compared to $16.4 million for the same period in 2024.
In pre-market trading on NYSE, ADC shares are up 7.58 percent to $4.54.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
